Article
The N6-methyladenosine-modified Pseudogene HSPA7 Correlates with the Tumor Microenvironment and Predicts the Response to Immune Checkpoint Therapy in Glioblastoma
2020-12-22
Abstract excerpt
<h4>Background: </h4> Glioblastoma (GBM), one of the most aggressive cancers in brain tumor type, have no effective and sufficient therapies. Identifying robust biomarkers of immune checkpoint blockade (ICB) therapy, a promising treatment option for GBM patients, are urgently warranted. <h4>Methods: </h4>: We comprehensively evaluated the m 6 A modification patterns of lncRNAs via m 6 A-sequencing (m 6 A-seq) data...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 64b7286c-64eb-58be-b08e-dd8cd0611bd6
- DOI
- 10.21203/rs.3.rs-130869/v1
